BREAKTHROUGHS IN COVID DIAGNOSTICS.

NEUOME PEPTIDES

Singapore based company Neuome Peptides Pte Ltd, a start-up backed by Mercatus Capital Singapore has developed a Peptide-based rapid antigen test kit, Trucov-flow. This technology detects SARS-COV-2 virus from saliva thus removing the need for swab and results come within 3-5 minutes maximum. It is ICMR validated and approved as a Novel Product ready for commercial launch in India which efficiently reduces the time taken in producing the diagnostic results without cross reactivity.

While talking to Medgate Today, Dr Rajanikanth, Director, Neuome Peptides Pte Ltd, Singapore, expressed his sincere gratitude to ICMR for approval of economic, efficient and easy to administer his Trucov-flow, Ultra -Sensitive Covid-19 Saliva based Rapid Antigen Test kit. This new diagnostics kit for all covid variants scored high on all key ICMR validation parameters like Sensitivity, Specificity Positive

Predictive Value and Negative Predictive Value has been validated at Laboratory Medicine and Molecular Diagnostics (LMMD), Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, under quality system procedure of NABL ISO 15189-2012 strictly adhering to ICMR protocols. This Rapid antigen test kits with expiry time of two years from date of production, will be commercially produced by Immunoscience Pvt Ltd in India and nationally and globally marketed by Neuome Peptides Pte Ltd, Singapore.